What Should We Do Next Quarter?
in HealthTech & Digital Health

The short answer

Most quarterly plans fail when at-risk share commitments outrun the observable window on engagement rates and attributed outcomes. Digital health companies carry a specific bind here — outcomes risk is being signed faster than the company can learn whether it can carry it — a 12-month measurement window against an 11-month sales cycle. Until that is priced, at-risk revenue share will keep moving for reasons nobody can attribute, and the debate about return per initiative will stay a matter of opinion.

A quarter contains a fixed amount of clinical and operational attention plus a fixed gross margin pool, and most plans sign at-risk revenue share faster than the company can confirm it can carry the outcomes. The result is not declared failure but silent triage: the organisation delivers the subset of enrolled members it can reach and nobody records which parts of the attributed outcomes were dropped.

A plan that survives contact ranks candidate moves by return on at-risk share, checks each against the PMPM and engagement rate capacity actually available, and sequences them so the first improves the data that validates the second. Three real priorities beat twelve stated ones every time.

The part almost always missing is the stopping rule — the engagement rate or logo churn threshold that would say a chosen at-risk contract is not working, defined before the contract is signed rather than argued about after the measurement window closes.

How to tell this is actually your problem

These three together are the signature. One on its own usually points somewhere else.

✓ Last quarter's at-risk share grew while engagement rate data for the prior cohort remained incomplete and nobody formally paused further signings
✓ Priorities are listed as PMPM targets and attributed outcomes but not ranked against current gross margin or logo churn exposure
✓ No at-risk contract has a written engagement rate or PMPM threshold that would trigger exit

The move that usually makes it worse. Signing every at-risk share that clears legal and sales, which guarantees the organisation's capacity on engagement and outcomes chooses the actual portfolio by default.

Who this is for — and who it is not

It is for you if you run or finance a digital health company and last quarter's plan was partly done and nobody formally dropped anything. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.

It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.

Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.

What this looks like when the analysis is actually run

Below is an excerpt from a real run of this analysis on a digital health company. It is a sample profile rather than a customer, and it is unedited engine output — this is the format you get, on your own numbers.

The subject is Vantabridge Health, a sample company profile used for testing rather than a customer — $62M ARR, 340,000 enrolled members.

This is one move out of a full analysis. Read a complete report — every page, no email required.

What the engine does with this question

This question routes to Growth Portfolio Framework, one of 29 engagements the platform runs. For digital health companies it works through at-risk revenue share, engagement rate, gross margin and logo churn, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.

You watch the analysis get built before paying anything. Read a complete report here if you would rather see the depth first.

Questions people ask about this

How many priorities should a quarter have?

As many as your real capacity supports, which in most small and mid-sized businesses is two or three. The number is arithmetic, not philosophy.

How do I choose between initiatives that all seem important?

Rank by return on the capacity each consumes, then by reversibility. When two are close, do the one you can stop.

What if circumstances change mid-quarter?

That is what the stopping rules are for. A plan with pre-agreed failure conditions can be changed on evidence rather than on argument, which is the difference between adapting and drifting.

Is this different in healthtech & digital health than in other industries?

Materially, yes. Outcomes risk is being signed faster than the company can learn whether it can carry it — a 12-month measurement window against an 11-month sales cycle — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are at-risk revenue share, engagement rate, gross margin, and an answer built on industry-general benchmarks will usually point at the wrong one first.

What data do I need before this analysis is worth running for a digital health company?

Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on at-risk revenue share and engagement rate. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.

When is Percision the wrong tool?

Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.

Does Percision replace a lawyer, tax advisor, auditor, or AI implementation team?

Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.